PolandPoland

European AIDS Conference: Biotechnology Fighting HIV Threat

23.11.2003

Warsaw - The Polish capital hosted the 9th European AIDS Conference (EACS) from October 25-29. As Europe is moving fast in the fight against HIV, approximately 3,000 visitors at this year's conference venue - the Warsaw International Expo-centre EXPO XXI (see photo) - affirmed the very high interest in this topic.
Among the latest results of retroviral therapy and the presentation of the 48 week in treatment-data of F. Hoffmann-La Roche's fusion inhibitor and potential block buster Fuzeon, modern biotechnological approaches were discussed thoroughly. Prof Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Switzerland, debated the pros and cons of HIV-vaccines. As companies like Merck, Aventis, GSK, Bavarian Nordic and Acambis are already developing vaccine candidates using different vectors and are conducting pre- and even clinical trials, this new approach in the fight against HIV still has to suffer many setbacks. Early this year the vaccine AIDSVAX by the U.S. company VaxGen Inc. flunked phase III trials. The future of the once promissing drug candidate is still uncertain.

PolandPoland

29.04.2009

Warsaw/Washington – The US Department of Agriculture (USDA) has criticised the draft law on genetically modified organisms (GMOs) that Poland recently submitted to the European Commission. The rules defined in the law “will...

PolandPoland

21.02.2009

Kraków – According to a report from Kraków-based PMR Ltd, the Czech Republic and Poland are on top in eastern Europe when it comes to outsourcing clinical trials and contract manufacture. The market analysis outlines 160...

PolandPoland

21.02.2009

Szczecin – The West-Pomeranian Center for Advanced Technologies and the German regional cluster BioCon Valley are setting up a German-Polish contact point for the life sciences. The long-term goal of the cooperation, which will...

PolandPoland

21.02.2009

Raszyn Rybie – Polish Euroimplant S.A. has received a66,000 in funding from the National Center for Research and Development (NCBiR) for product development, according to CE.biotech.com. The specialist firm for tissue...

PolandPoland

21.02.2009

Warsaw – Polish insulin and antibiotics maker Bioton S.A. has shuffled its mana­gement board after announcing that an expected deal failed to materialise. In mid-January, after Prokom Investments (Gdynia) proved unable to sell...

PolandPoland

21.02.2009

Kraków – BioCentrum Sp. zo.o. is expanding contract research activities for the bio-pharmaceutical industry. In December, the Polish specialist for preclinical ADME, cell-based assays, protein characterisation, antibody, enzyme...

PolandPoland

23.01.2009

Warsaw – Polish insulin and antibiotics maker Bioton S.A. has shuffled its management board after a failed deal hit the news. When Prokom Investments (Gdynia) failed to sell a 33.3% stake in Bioton to Jerzy Starak’s Polpharma for...

PolandPoland

11.11.2008

Warsaw – In August, the lower chamber of the Polish parliament approved a 31m EUR programme for the protection of mental health to run from 2009-2013. The programme, which is to be financed from the state budget and EU funds,...

PolandPoland

18.08.2008

Portoroz – Around 120 international bioprocessing experts met at the 3rd Monolith Summer Symposium at Portoroz to discuss how monolith chromatography can eliminate current bottlenecks in downstream processing of biological drugs....

PolandPoland

20.05.2008

Krakow – Selvita Sp. z o.o., a newly founded service provider to the biotechnological and pharmaceutical industries, has taken over biotech tools and services supplier BioCentrum Ltd. At the end of March, Selvita acquired 64% of...

Displaying results 31 to 40 out of 108

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-poland/browse/3/article/european-aids-conference-biotechnology-fighting-hiv-threat.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4290.4%
  • CO.DON2.51 EUR191.9%
  • PAION2.43 EUR164.1%

FLOP

  • CYTOS0.25 CHF-93.9%
  • MEDIGENE4.53 EUR-69.2%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 01.09.2014


Current issue

All issues

Product of the week

Products